• Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close

    1 month ago - By Healio

    On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant's most prized possession: Humira.
    Just 2 weeks prior, AbbVie had filed a lawsuit of its own against Alvotech - currently seeking FDA approval for its Humira biosimilar AVT02 - accusing Alvotech of patent infringement related to that biosimilar application.
    This volley of dueling legal actions is merely the latest chapter in what has been a
    Read more ...